605 related articles for article (PubMed ID: 16249934)
21. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
Tré-Hardy M; Traore H; El Manssouri N; Vanderbist F; Vaneechoutte M; Devleeschouwer MJ
Int J Antimicrob Agents; 2009 Oct; 34(4):370-4. PubMed ID: 19505804
[TBL] [Abstract][Full Text] [Related]
22. Effects of iron depletion on antimicrobial activities against planktonic and biofilm Pseudomonas aeruginosa.
Cai Y; Yu XH; Wang R; An MM; Liang BB
J Pharm Pharmacol; 2009 Sep; 61(9):1257-62. PubMed ID: 19703377
[TBL] [Abstract][Full Text] [Related]
23. An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections.
Koeva M; Gutu AD; Hebert W; Wager JD; Yonker LM; O'Toole GA; Ausubel FM; Moskowitz SM; Joseph-McCarthy D
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923873
[TBL] [Abstract][Full Text] [Related]
24. [Discrepancy in the disk diffusion susceptibility test of Pseudomonas aeruginosa strains isolated from cystic fibrosis patients after anaerobic preincubation and its potential clinical relevance].
Cafini F; García-Rey C; Bas P; Gómez-Lus ML; Sánchez I; Vázquez S; Prieto J
Rev Esp Quimioter; 2012 Dec; 25(4):269-73. PubMed ID: 23303259
[TBL] [Abstract][Full Text] [Related]
25. Interaction between tobramycin and CSA-13 on clinical isolates of Pseudomonas aeruginosa in a model of young and mature biofilms.
Nagant C; Tré-Hardy M; El-Ouaaliti M; Savage P; Devleeschouwer M; Dehaye JP
Appl Microbiol Biotechnol; 2010 Sep; 88(1):251-63. PubMed ID: 20625718
[TBL] [Abstract][Full Text] [Related]
26. Fosfomycin and tobramycin in combination downregulate nitrate reductase genes narG and narH, resulting in increased activity against Pseudomonas aeruginosa under anaerobic conditions.
McCaughey G; Gilpin DF; Schneiders T; Hoffman LR; McKevitt M; Elborn JS; Tunney MM
Antimicrob Agents Chemother; 2013 Nov; 57(11):5406-14. PubMed ID: 23959314
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of Aerosolized Rifaximin versus Tobramycin for Treatment of Pseudomonas aeruginosa Pneumonia in Mice.
Kirby BD; Al Ahmar R; Withers TR; Valentine ME; Valentovic M; Long TE; Gaskins JR; Yu HD
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010865
[No Abstract] [Full Text] [Related]
28. Enhancement of antimicrobial activity against pseudomonas aeruginosa by coadministration of G10KHc and tobramycin.
Eckert R; Brady KM; Greenberg EP; Qi F; Yarbrough DK; He J; McHardy I; Anderson MH; Shi W
Antimicrob Agents Chemother; 2006 Nov; 50(11):3833-8. PubMed ID: 16940063
[TBL] [Abstract][Full Text] [Related]
29. PEGylation of Tobramycin Improves Mucus Penetration and Antimicrobial Activity against Pseudomonas aeruginosa Biofilms in Vitro.
Bahamondez-Canas TF; Zhang H; Tewes F; Leal J; Smyth HDC
Mol Pharm; 2018 Apr; 15(4):1643-1652. PubMed ID: 29514003
[TBL] [Abstract][Full Text] [Related]
30. Combination of hypothiocyanite and lactoferrin (ALX-109) enhances the ability of tobramycin and aztreonam to eliminate Pseudomonas aeruginosa biofilms growing on cystic fibrosis airway epithelial cells.
Moreau-Marquis S; Coutermarsh B; Stanton BA
J Antimicrob Chemother; 2015 Jan; 70(1):160-6. PubMed ID: 25213272
[TBL] [Abstract][Full Text] [Related]
31. Oxygen limitation contributes to antibiotic tolerance of Pseudomonas aeruginosa in biofilms.
Borriello G; Werner E; Roe F; Kim AM; Ehrlich GD; Stewart PS
Antimicrob Agents Chemother; 2004 Jul; 48(7):2659-64. PubMed ID: 15215123
[TBL] [Abstract][Full Text] [Related]
32. Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model.
Tré-Hardy M; Macé C; El Manssouri N; Vanderbist F; Traore H; Devleeschouwer MJ
Int J Antimicrob Agents; 2009 Jan; 33(1):40-5. PubMed ID: 18801647
[TBL] [Abstract][Full Text] [Related]
33. Characterization of clonal strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients in Ontario, Canada.
Beaudoin T; Aaron SD; Giesbrecht-Lewis T; Vandemheen K; Mah TF
Can J Microbiol; 2010 Jul; 56(7):548-57. PubMed ID: 20651854
[TBL] [Abstract][Full Text] [Related]
34. Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing.
Breen SKJ; Harper M; López-Causapé C; Rogers KE; Tait JR; Smallman TR; Lang Y; Lee WL; Zhou J; Zhang Y; Bulitta JB; Nation RL; Oliver A; Boyce JD; Landersdorfer CB
Int J Antimicrob Agents; 2024 Jun; 63(6):107161. PubMed ID: 38561094
[TBL] [Abstract][Full Text] [Related]
35. Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections.
Rojo-Molinero E; Macià MD; Rubio R; Moyà B; Cabot G; López-Causapé C; Pérez JL; Cantón R; Oliver A
Antimicrob Agents Chemother; 2016 May; 60(5):2912-22. PubMed ID: 26926631
[TBL] [Abstract][Full Text] [Related]
36. Stationary biofilm growth normalizes mutation frequencies and mutant prevention concentrations in Pseudomonas aeruginosa from cystic fibrosis patients.
García-Castillo M; del Campo R; Baquero F; Morosini MI; Turrientes MC; Zamora J; Cantón R
Clin Microbiol Infect; 2011 May; 17(5):704-11. PubMed ID: 20673272
[TBL] [Abstract][Full Text] [Related]
37. Susceptibility of Pseudomonas aeruginosa Recovered from Cystic Fibrosis Patients to Murepavadin and 13 Comparator Antibiotics.
Ekkelenkamp MB; Cantón R; Díez-Aguilar M; Tunney MM; Gilpin DF; Bernardini F; Dale GE; Elborn JS; Bayjanov JR; Fluit A
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767727
[TBL] [Abstract][Full Text] [Related]
38. Potentiation of Tobramycin by Silver Nanoparticles against Pseudomonas aeruginosa Biofilms.
Habash MB; Goodyear MC; Park AJ; Surette MD; Vis EC; Harris RJ; Khursigara CM
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848007
[TBL] [Abstract][Full Text] [Related]
39. Development of a rapid colorimetric time-kill assay for determining the in vitro activity of ceftazidime and tobramycin in combination against Pseudomonas aeruginosa.
Moriarty F; Elborn S; Tunney M
J Microbiol Methods; 2005 May; 61(2):171-9. PubMed ID: 15722142
[TBL] [Abstract][Full Text] [Related]
40. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.
Moskowitz SM; Foster JM; Emerson J; Burns JL
J Clin Microbiol; 2004 May; 42(5):1915-22. PubMed ID: 15131149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
